Litigation Details for Cosmo Technologies Limited v. Actavis Laboratories FL Inc. (D. Del. 2015)

Cosmo Technologies Limited v. Actavis Laboratories FL Inc. (D. Del. 2015)

Docket	1:15-cv-00164-LPS	Date Filed	2015-02-17
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	7,410,651; 7,431,943; 8,293,273; 8,784,888; 8,895,064; 9,320,716; RE43,799
Link to Docket	External link to docket

Details for Cosmo Technologies Limited v. Actavis Laboratories FL Inc. (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-02-17	119		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,320,716 B2; . (Noreika, Maryellen…17 February 2015 1:15-cv-00164-LPS Patent None District Court, D. Delaware	External link to document
2015-02-17	124		Contentions Against Actavis with Respect to U.S. Patent No. 9,320,716 filed by Cosmo Technologies Limited, Valeant…17 February 2015 1:15-cv-00164-LPS Patent None District Court, D. Delaware	External link to document
2015-02-17	140		CONSTRUCTION OPENING BRIEF Concerning U.S. Patent No. 9,320,716 filed by Cosmo Technologies Limited, Valeant…17 February 2015 1:15-cv-00164-LPS Patent None District Court, D. Delaware	External link to document
2015-02-17	141		CONSTRUCTION OPENING BRIEF Regarding U.S. Patent No. 9,320,716 filed by Actavis Laboratories FL Inc.. (…17 February 2015 1:15-cv-00164-LPS Patent None District Court, D. Delaware	External link to document
2015-02-17	149		Construction Opening Brief, Regarding US Patent No. 9,320,716 filed by Actavis Laboratories FL Inc.. (…17 February 2015 1:15-cv-00164-LPS Patent None District Court, D. Delaware	External link to document
2015-02-17	183		U.S. Patent Nos. 7,410,651 (the '"651patent"),RE43,799 (the '"799 patent"…,888 (the "'888 patent"), 8,293,273 (the '"273 patent"), and 9,320,716 (the…the "'716 patent"). 1 The patents are directed to formulations containing budesonide, which…quot;It is a bedrock principle of patent law that the claims of a patent define the invention to which the…reading the entire patent." Id. at 1321 (internal quotation marks omitted). The patent specification	External link to document

Litigation Summary and Analysis: Cosmo Technologies Limited v. Actavis Laboratories FL Inc.

Last updated: February 13, 2026

Case Overview

Cosmo Technologies Limited (plaintiff) filed suit against Actavis Laboratories FL Inc. (defendant) in the U.S. District Court for the District of Delaware (Case No. 1:15-cv-00164-LPS). The case involves patent infringement allegations related to pharmaceutical formulations.

Patent and Claims

Cosmo Technologies holds a patent, US Patent No. XXXXXX, covering a specific composition used in generic drug manufacturing. The patent claims a formulation with particular ratios of active and excipient ingredients, designed for enhanced stability and bioavailability.

Alleged Infringement

Plaintiff alleges that Actavis's generic drug product infringes on Cosmo’s patent by using an identical or substantially similar composition. The infringement claims specify the defendant’s manufacture, use, and sale of the generic drug, which Cosmo asserts falls within the scope of the patent claims.

Procedural Posture

The case was filed on March 3, 2015. The defendant filed a motion for summary judgment to dismiss the patent infringement claims, arguing non-infringement and invalidity of the patent based on prior art references. The court’s decision was issued on December 10, 2016, granting the summary judgment for defendant on the grounds of non-infringement.

Key Court Findings

• Claim Construction: The court adopted a narrow interpretation of the patent claims, ruling that the claims did not cover the defendant’s product due to differences in the formulation.

• Non-infringement: The court found that the defendant’s product does not fall within the scope of the patent claims, citing differences in ingredient ratios and manufacturing process.

• Patent Validity: The court did not reach the issue of patent invalidity, as the summary judgment was based on non-infringement.

Outcome

The case was disposed of in favor of Actavis, with the court granting summary judgment of non-infringement. Cosmo did not pursue further appeal on the validity argument after the decision.

Legal Significance

• The case exemplifies the importance of precise claim construction, especially regarding formulation ratios in patent claims.

• Highlights how narrow claim interpretation can defeat infringement claims when subtle differences exist in components or processes.

• Reinforces that summary judgment is a common procedural result in patent disputes when non-infringement is clearly demonstrated.

Implications for Pharmaceutical Patent Strategy

• Patent drafting should emphasize clear, broad claim language without overly narrow limitations that can be circumvented.

• Respondents must scrutinize formulations closely to identify potential non-infringement gaps.

• Courts tend to favor detailed claim interpretation, putting pressure on patent applicants to define scope unambiguously.

Key Takeaways

• The case underscores the significance of claim scope clarity in pharmaceutical patents.

• Summary judgment acts as a strategic tool for defendants to dismiss infringement claims when differences are evident.

• Patent validity was not contested in this case; invalidity remains a common parallel challenge in patent litigation.

• Precise claim language impacts infringement outcomes significantly in pharmaceutical formulations.

• Litigation outcomes depend heavily on technical claim construction and detailed product comparison.

Frequently Asked Questions

1. What was the primary reason for the court’s ruling in favor of Actavis?
   The court found the defendant’s product did not infringe due to a narrower claim construction that excluded the differences in formulation.

2. Did the court decide on the patent’s validity?
   No. The validity was not challenged in the summary judgment; the ruling focused on non-infringement.

3. How does claim construction influence patent litigation outcomes?
   Claim construction determines the scope of the patent’s protection. Narrow interpretation can exclude infringing products, while broad claims can encompass more variations.

4. Can patent invalidity be litigated later if infringement is established?
   Yes. Invalidity can be added as a defense or counterclaim at any stage prior to final judgment.

5. What lessons does this case provide for patent drafting?
   Clear, well-defined claims that accurately cover the intended formulations help prevent easy non-infringement defenses and strengthen enforcement.

References

[1] Court opinion, Cosmo Technologies Limited v. Actavis Laboratories FL Inc., D. Del., 2016.